Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.

Authors

null

John Paul Flores

Tufts Medical Center, Boston, MA

John Paul Flores , Paul Mathew

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02500901

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS5095)

DOI

10.1200/JCO.2016.34.15_suppl.TPS5095

Abstract #

TPS5095

Poster Bd #

441a

Abstract Disclosures

Similar Posters